Precision BioSciences, Inc. (DTIL)

Market Cap	173.83M +332.7%
Revenue (ttm)	34.26M -50.1%
Net Income	-45.72M
EPS	-3.56
Shares Out	24.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,100,367
Open	6.88
Previous Close	6.93
Day's Range	6.56 - 7.59
52-Week Range	3.53 - 8.82
Beta	1.32
Analysts	Strong Buy
Price Target	60.00 (+753.49%)
Earnings Date	Mar 12, 2026

About DTIL

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 28, 2019
• Employees: 67
• Stock Exchange: NASDAQ
• Ticker Symbol: DTIL
• Website: https://precisionbiosciences.com

Analyst Summary

According to one analyst, the rating for DTIL stock is "Strong Buy" and the 12-month stock price target is $60.0.

Price Target

$60.0

(753.49% upside)

Analyst Consensus: Strong Buy